AUS
NZ
UK
CA
USA
IND
Highlights
- - Imugene extends cash runway to late 2025 through strategic capital injection.
- - Funding supports clinical trials for key programs, including azer-cel and VAXINIA.
- - Additional cost-saving measures strengthen financial position.
Imugene (ASX:IMU) has announced a significant step in strengthening its financial position, raising up to A$46 million through convertible notes and warrants. This funding aims to accelerate the company’s progress in advancing its clinical pipeline, which includes pivotal programs such as azer-cel, onCARlytics, and VAXINIA.
The financing arrangement includes A$20 million in senior, unsecured, zero-coupon convertible notes, with an additional A$26 million available through unlisted warrants. These funds extend the company’s cash runway to late 2025, enabling it to focus on generating key clinical data over the coming months.
Strategic Financial Backing
The convertible notes issued to CVI Investments, Inc., an affiliate of Heights Capital Management, are set to mature in five years and are interest-free. The conversion price for these notes is set at a 25% premium to Imugene’s closing price as of December 20, with price adjustments every six months based on market trends.
In addition to the convertible notes, the unlisted warrants carry a five-year tenure and are priced at A4.94 cents per share. This structured funding provides the flexibility needed to support the company’s ambitious clinical development goals without incurring traditional financing costs like interest.
Supporting Clinical Innovation
The capital will be directed toward the continued development of Imugene’s promising therapeutic programs. Azer-cel, onCARlytics, and VAXINIA are among the key initiatives expected to benefit from this infusion, with critical data readouts anticipated in the next year.
According to Imugene CEO Leslie Chong, the funding highlights confidence in the company’s innovative approaches. “This investment validates our growth strategy and supports the advancement of Imugene’s promising pipeline,” Chong said.
Operational Cost Savings
To complement this funding, Imugene has implemented cost-saving measures, including optimizing manufacturing operations, workforce adjustments, and administrative expense reductions. These initiatives further extend the company’s financial runway, providing additional resources to focus on advancing its programs.
Focus on Growth
With this substantial financial backing, coupled with operational efficiency efforts, Imugene is well-positioned to make significant progress in its clinical trials. This strategic funding arrangement not only bolsters its ability to generate clinical data but also underscores investor confidence in the company’s approach and potential for growth.
The combination of capital injection and cost-saving measures ensures that Imugene remains financially resilient, with a clear path to advancing its innovative pipeline through clinical development.
